Animal Pharm is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. Please do not redistribute without permission.

Printed By


Veterinary cancer vaccine nears the market

Morphogenesis, a US biotechnology company, plans to increase production of ImmuneFX, its US-patented cancer vaccine for companion animals. The product is in late pre-clinical trials, and should be ready for clinical Phase I filing within a year, says the company. The market for pet cancer treatment is growing in the US and Europe, it estimates, with the US canine lymphosarcoma market alone worth over $200m annually. "Morphogenesis has made significant progress over the last year, potentially leading to early revenues for the business," says non- executive director Dr Satu Vainikka, in a statement to investors.



What to read next




Ask The Analyst

Please fill in the form below to send over your enquiry or check the Ask The Analyst Page to find out more about the service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts